Clinical Study
Current Genetic Epidemiology of β-Thalassemias and Structural Hemoglobin Variants in the Lazio Region (Central Italy) Following Recent Migration Movements

Antonio Amato,1 Maria Pia Cappabianca,1 Alessia Colosimo,2 Maria Perri,1 Paola Grisanti,1 Ivo Zaghis,1 Donatella Ponzini,1 and Maria Lerone1

1 ANMI Onlus, Centro Studi Microcitemie, Rome, Italy
2 Department of Comparative Biomedical Sciences, University of Teramo, Italy

Correspondence should be addressed to Antonio Amato, microcitemieroma@blod.info
Received 10 December 2009; Revised 5 July 2010; Accepted 30 August 2010

Academic Editor: Frits R. Rosendaal

Copyright © 2010 Antonio Amato et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The aim of this study was to describe the changing pattern of mutational spectrum of β-thalassemia (β-thal) in the Lazio region (Central Italy), as consequence of recent demographic variations. From 1994 until present, 256 immigrant subjects with hemoglobin disorders (including 191 heterozygotes and 65 homozygotes or compound heterozygotes) coming from 44 different foreign countries, have been molecularly characterized. 14 β-globin gene mutations were identified and their frequencies reflect different ethnic origins: 8 of these mutations account for 76.97% of all molecular defects, while 6 of them are much rare, representing less than 2% of the total. These data differ, both in type and percentage, from the mutational spectrum detected in the native population in 1995. Since a few defects are prevalent in each country, a proper strategy for the identification of mutations in immigrant individuals relies on the prior knowledge of their frequency in native ethnic group.

1. Introduction

The inherited disorders of hemoglobin (including structural hemoglobin variants and α- and β-thalassemias) show a marked molecular variability in the different ethnic groups that mainly results from heterogeneous mutations occurring at the α- and β-globin loci. At present, more than 600 and 700 mutations involving the α-globin and the β-globin genes, respectively, have been described worldwide [1].

In the Lazio region (Latium) of Central Italy, β-thalassemia (β-thal) is relatively common among the native population with a prevalence of 2.4% [2]. The “Centro Studi Microcitemie Roma” (CSMR) has been leading since 35 years a prevention program of hemoglobinopathies and thalassemias in Latium by a strategic plan including three different types of actions: information to the population, healthy carriers detection, and genetic counselling for at-risk couples [3].

The epidemiology of hemoglobin disorders has been drastically changed since the early 1980s–1990s [4] when a consistent and progressive migration from emerging countries has started in Italy, particularly in Latium. For this reason, it is fundamental to adopt novel strategies to include immigrant people in each regional prevention program. To this aim, to correctly evaluate the current mutational spectrum of β-thal and structural hemoglobin variants in Latium, a cohort of 256 immigrant subjects with hemoglobin disorders, who are now resident in the region, has been molecularly characterized. These subjects have been analyzed by molecular studies, because they were carriers, partners of couples at risk of having children affected with Thalassemia major or intermedia, or because they were affected.

In addition, a comparison with a previous study that analyzed 203 prospective at-risk couples, who were native of Latium [5], has been carried out. This paper allows of verifying the changes occurred at the molecular level in
2 Advances in Hematology

| Molecular defects | Frequency (n:191) | Europe (n:77) | Africa (n:58) | Asian countries (n:42) | Middle Eastern countries (n:7) | South Central America (n:7) |
|-------------------|------------------|--------------|--------------|----------------------|-------------------------------|-----------------------------|
|                   | n                | %            | 40.31%       | 30.37%               | 21.99%                        | 3.66%                        |
| Hb S              | 41               | 21.47        | 4            | 36                   |                               | 1                           |
| IVS-I-110 (G → A) | 30               | 15.71        | 27           | 3                    |                               |                             |
| Hb E              | 17               | 8.90         |              |                      |                               |                             |
| Cod 39 (CAG → TAG)| 17               | 8.90         | 17           |                      |                               |                             |
| IVS-I-5 (G → A, G → C) | 16           | 8.38         |              |                      | 14                            | 2                           |
| IVS-I-6 (T → C)   | 11               | 5.76         |              |                      | 1                             | 2                           |
| Hb C              | 8                | 4.19         |              |                      | 6                             | 2                           |
| Cod 82-83 (-G)    | 3                | 1.57         |              |                      | 5                             | 1                           |
| Hb Knossos        | 3                | 1.57         |              |                      |                               |                             |
| Hb Lepore         | 3                | 1.57         |              |                      | 2                             |                             |
| IVS-II-848(C → A) | 3                | 1.57         |              |                      | 1                             |                             |
| Cod 41-42(-TTCT)  | 2                | 1.05         |              |                      |                               |                             |
| Cod 51 (-C)       | 2                | 1.05         |              |                      | 2                             |                             |
| Deletional mutations | 8               | 4.19         |              |                      | 1                             |                             |
| Other abnormal Hbs | 9                | 4.71         |              |                      | 3                             |                             |
| Other rare mutations | 11             | 5.76         |              |                      |                               |                             |

3. Results

Between 1994 and 2007, at the CSMR, a total of 167,235 individuals has been examined by haematological, haemoglobin, and biochemical analyses. Of this total number, 10,353 were immigrant, indicating a progressive increase in the above-mentioned years (from 2.7% until 9.8%). Among the 10,353 individuals, 7869 resulted to be wild type while 2484 were either carriers or affected [9] (Table 3(a)).

The 256 individuals, molecularly examined, were mainly coming from East Europe (102 subjects: Albania was included in this group for geographical reasons) and Africa (86 subjects), and in lower amount from Asia (60 subjects) and Central-Southern America (8 subjects). These 256 individuals were divided in 110 healthy β-thal carriers, 81 carriers of hemoglobin variants, and 65 homozygous or compound heterozygous patients.

From familiar data involving 191 healthy carriers analyzed at our molecular biology laboratories from 1994 until present (110 healthy β-thal carriers and 81 carriers of several hemoglobinopathies), 40.31% were coming from East Europe, mainly from Albania; 30.37% from Africa, mainly from Egypt and Central-Western Africa (Senegal, Cote d’Ivoire, Ghana, Nigeria, Congo, Burkina Faso); 25.65% from Asia (Asian and Middle Eastern countries), mainly from Bangladesh (Table 1).
Table 2: Interactions between different alleles in the β globin genes (65 immigrant patients).

| β0/β0      | β0/β+   | β+β+   | Hb variants       |
|------------|---------|--------|-------------------|
| Cd 39 homozygous (4) | Cd 39 / IVS-I 110 (2) | IVS-I 110 homozygous (5) | Hb S/Hb S (19) |
| Cd 39/IVS-I 1 1 (1) | Cd 8/IVS-I 6 1 (1) | IVS-I 110/Hb Knossos (1) | Hb S/Hb C (3) |
| Cd 10/Cd 16 homozygous (1) | Cd 41-42/IVS-I 1 1 (1) | IVS-I 110/IVS-II 848 (2) | Hb S/Cd 39 (1) |
| Cd 6 homozygous (1) | IVS-I 1/IVS-I 110 (1) | IVS-I 110/IVS-I 1 (1) | Hb S/Cd 82-83 (1) |
| Cd 39/Cd 82-83 (1) | Hb Lepore/IVS-I 5 (1) | IVS-I 6/30 (1) | Hb C homozygous (3) |
| Cd 51/Hb Lepore (1) |                   |           | Hb E homozygous (5) |
|             |                   |           | Hb E/deletion (1) |
|             |                   |           | IVS-I 6 homozygous (3) |
|             |                   |           | IVS-I 5 homozygous (1) |

Table 3

| Years       | Examined subjects (n) | Immigrants (n) | Carriers of affected % | Carriers % | Affected % |
|-------------|-----------------------|----------------|------------------------|------------|------------|
| 1994–2007   | 167.235               | 10.353         | 6.2                    | 2484       | 24.0       |

(b) Molecular tests for definitive diagnosis (carriers and affected individuals)

| Years       | Examined subjects (n) | Immigrants (n) | % |
|-------------|-----------------------|----------------|---|
| 1994–1998   | 950                   | 26             | 2.74 |
| 1999–2003   | 2,047                 | 93             | 4.54 |
| 2004–2008   | 2,725                 | 137            | 5.03 |
| 1994–2008   | 5,722                 | 256            | 4.47 |

This novel heterogeneous population of immigrants has deeply modified the mutational spectrum of β-thal alleles that was observed in this Italian region 14 years ago. In fact, a previously reported study, carried out on 406 individuals of Latium descendant, detected 8 more common mutations (Cd 39, IVSI-110, IVSI-745, IVSI-6, IVSI-1, IVSI-II, Frameshift 6, and Hb Lepore) that accounted for 93.4% of all β-thal alleles in the region [5]. Conversely, the present paper shows that 8 partially different mutations (HbS, IVSI-110, HbE, cod 39, IVSI-5, IVSI-6, HbC, and IVSI-1) account for 76.97% of all β-globin molecular defects in the foreign population (Table 1). Due to the wide ethnic heterogeneity of these heterozygous subjects, other molecular defects were detected. These include several abnormal hemoglobins (that are usually rare), some deletional mutations (Sicilian, Indian, Filipino, and a novel 12-bp deletion at the beginning of the β globin second intron found in a woman of Indian descent [10]) and other rare β-thal alleles (Table 1).

A few of the most common mutations in Latium are also present in patients originating from East Europe [10], although with different frequencies. In addition, some particular hemoglobin variants such as HbS, in Italy are predominant only in Southern populations [11], were also detected in 4 subjects accounting for 5.19% of the total (Table 1).

In Asian and Middle-Eastern populations, the HbE is mainly present [12] (17 subjects out of 49, corresponding to 34.69%) and the IVSI-5 (G→C) mutation [13] (16 subjects corresponding to 32.65%), that in Latium is present only in the G→A variant with a frequency of 0.45% [5].

In African populations, the hemoglobin variants are the most common alterations [14], including 36 subjects with HbS (62.07%), 6 subjects with HbC (10.34%), and 3 subjects with Hb Knossos [15] (5.17%) (Table 1).

All the mutations that have been detected in 191 healthy carriers were also revealed in different combinations in 65 relatives, who were homozygous or compound heterozygous patients (Table 2).

4. Discussion

Latium is the Italian region with the highest incidence of most recent immigration. From published data in 2009 by Caritas/Osservatorio Romano sulle Migrazioni [16], out of a total of 11.69% immigrants who are resident in Latium [17], 30.70% are coming from Romania, 6.81% from Philippines, 5.39% from Poland, 4.97% from Albania, 3.33% from Ukraine, and 3.05% from Peru. These data do not perfectly match with the ethnic variety of individuals who arrived at our CSMR laboratory, for cultural, social, and also genetic reasons. In fact, the Philippine population is absent in our cohort of samples because in that country is prevalent the α-thal and not the β-thal [18], while Romanians are less represented for the rare presence (0.5%) of β-thal in that country [19].

During the last 15 years, the number of molecular analyses carried out at CSMR on foreign patients or healthy carriers has been progressively increased; in a five-year period (2004–2008) has been quintupled, if compared to the first five years (1994–1998) (Table 3(b)). Although a few and very comprehensive studies have determined the influence of recent immigration movements by updating the spectrum of β-globin mutations in Northern and Western Europe, or in
the United Kingdom [20, 21], such a similar epidemiological study regarding the changing spectrum of mutations in Italy has not been carried out. This paper is aimed at fulfilling this lack of information by determining the novel spectrum of \( \beta \)-globin mutations observed in immigrant populations in the Latio region from 1994 until present. In our Molecular Biology Laboratory, from 1994 to present, we have detected 256 foreign subjects with hereditary hemoglobin disorders (4.47% of the total molecular analysis carried out in the considered 15 years) (Table 3(b)). If compared to the molecular analyses carried out in 1995 and involving only heterozygotes who were native of Latium [5], the present research highlighted a wider heterogeneity of all mutations in immigrant subjects. Although also in this cohort of individuals some mutations are more common, it is evident the presence of structural hemoglobin variants that were absent in the Latium population in the recent past. As expected, a similar heterogeneity was also evident in carriers of two molecular alterations (i.e., patients affected with thalassemia major, thalassemia intermedia, and hemoglobinopathies) (Table 2).

The novel mutations that in the recent past were never described in the Latium native population are obviously common in the countries of origin of the immigrant \( \beta \)-thal carriers; for example: cod 82-83 (-G) in Albania, cod 10 (C → A)/cod 16 (-C) in Afghanistan, cod 36-37 (-T) in Santo Domingo, cod 41-42 (-TCTT) in Bangladesh, cod 51 (-C) in Romania, -29 (A → G) in Venezuela, and IVS II-654 (C → T) in China. Regarding the hemoglobin variants, those that are considered of scarce clinical relevance in our region, with the exception of the Hb Lepore (2.05%), the HbS is more frequent in African descendant individuals, the HbE is common in Asian subjects, while other variants such as HbC, Hb Lepore, and Hb Knossos are evident in individuals originating from countries in which these mutations are common.

Finally, some variants that are not relevant from a clinical point of view including Hb Kenitra in a subject from Nigeria, Hb G-Coushatta in a Iranian subject, Hb Hoshida in an Hungarian subject, have been detected by direct sequencing of the \( \beta \)-globin gene.

Of course, all the detected molecular defects only partially reflect the real variety that is present in each native country [22].

Nowadays, a suitable strategy for identifying the \( \beta \)-globin mutations needs the knowledge of the mutations, common or rare, that are present in the ethnic group to which the individuals under examination belong to. This information simplifies the diagnostic strategy because it allows to design the appropriate allele-specific primers, the digestion restriction enzymes, or the appropriate probes to detect the mutations that are more common in the patient’s country of origin. In addition, it is always fundamental to perform family studies for the identification of heterozygous mutations, in the case of patients carrying the association of two \( \beta \)-globin defects, and also for understanding the segregation of different genes that may modify the phenotype. The mutations that remain uncharacterized may be detected by direct automatic sequencing analysis of genomic DNA. It is becoming evident that in the present condition of uninterrupted and constant migration of foreign individuals, who are carriers of mutations that are rare in the Italian indigenous population, the use of commercial kits is not sufficient for the mutation detection in a such heterogeneous cohort of subjects.

In the Latium region of its competence, and starting from 1994, the CSMR was able to reduce to zero the number of affected offspring from unaware native couples, using a protocol that included a mass screening of boys and girls (of about 13 years old) who were attending the secondary school. This screening, joined to an adequate sanitary information, has allowed the precocious identification of healthy carriers. In addition, postdiagnosis genetic counselling has been able to give to the couples at risk all the medical information and the alternative options of prevention. In this way, all the informed carriers may decide by themselves according to their ethical or religious opinions.

Today, the main objective of CSMR is to inform also the foreign population of the risk [22, 23] and the possibility of prevention [24] to provide means of hematological and molecular diagnosis and to offer a proper service of genetic counselling.

References

[1] R. C. Hardison, D. H. K. Chui, B. Giardine et al., “HbVar. A relational database of human hemoglobin variants and thalassemia mutations at the globin gene server,” Human Mutation, vol. 19, no. 3, pp. 225–233, 2002.

[2] I. Bianco, B. Graziani, M. Lerone et al., “A screening programme for the prospective prevention of Mediterranean anaemia in Latium: results of seven years’ work,” Journal of Medical Genetics, vol. 21, no. 4, pp. 268–271, 1984.

[3] E. Silvestroni and I. Bianco, “Screening for microcytemia in Italy: analysis of data collected in the past 30 years,” American Journal of Human Genetics, vol. 27, no. 2, pp. 198–212, 1975.

[4] A. Amato, P. Grisanti, D. Ponzini et al., “Need of implementing thalassemia prevention strategies among immigrants: 13 years experience in Latium at Centro Studi Microcitemia Roma (CSMR),” Hematologica, vol. 93, supplement 3, p. 15, 2007.

[5] M. P. Cappabianca, L. Morlupi, S. Rinaldi, B. Graziani, and I. Bianco, “Le \( \beta \) microcitemie nel Lazio: varietà molecolari ed incidenza,” Progress in Medicine, vol. 51, pp. 41–43, 1995.

[6] S. A. Miller, D. D. Dykes, and H. F. Polesky, “A simple salting out procedure for extracting DNA from human nucleated cells,” Nucleic Acids Research, vol. 16, no. 3, p. 1215, 1988.

[7] N. Y. Varawalla, J. M. Old, R. Sarkar, R. Venkatesan, and D. J. Weatherall, “The spectrum of \( \beta \)-thalassemia mutations on the Indian subcontinent: the basis for prenatal diagnosis,” British Journal of Haematology, vol. 78, no. 2, pp. 242–247, 1991.

[8] A. Colosimo, V. Guida, A. De Luca et al., “Reliability of DHPLC in mutational screening of \( \beta \)-globin (HBB) alleles,” Human Mutation, vol. 19, no. 3, pp. 287–295, 2002.

[9] A. Amato, P. Grisanti, M. Lerone et al., “Prevention strategies for severe hemoglobinopathies in endemic and nonendemic immigration countries: the Latium example,” Prenatal Diagnosis, vol. 29, no. 12, pp. 1171–1174, 2009.
[10] M. De Angioletti, G. Lacerra, E. Boletini, F. Di Noce, G. Musollino, and C. Carestia, "β- and α-globin genotypes in Albanian patients affected β-globin gene disorders," *Haematologica*, vol. 87, no. 9, pp. 1002–1003, 2002.

[11] G. Schiliro, E. Mirabile, R. Testa, G. Russo-Mancuso, and S. P. Dibenedetto, "Presence of hemoglobinopathies in Sicily: a historic perspective," *American Journal of Medical Genetics*, vol. 69, no. 2, pp. 200–206, 1997.

[12] P. Pung-Amritt, V. S. Tanphaichitr, K. Tachavanich, L. Suwanto, and W. Glomglao, "Prevalence of Hb E from cord blood samples and after one year follow-up," *Southeast Asian Journal of Tropical Medicine and Public Health*, vol. 30, supplement 2, pp. 97–99, 1999.

[13] P. E. E. Vaz, C. B. Thakur, M. K. Banerjee, and S. G. Gangal, "Distribution of β-thalassemia mutations in the Indian population referred to a diagnostic center," *Hemoglobin*, vol. 24, no. 3, pp. 181–194, 2000.

[14] B. Chami, Y. Blouquit, J. Bardakdjian-Michau et al., "Hemoglobin variants in North Africa," *Hemoglobin*, vol. 18, no. 1, pp. 39–51, 1994.

[15] I. R. Hussein, S. A. Temtamy, A. El-Beshlawy et al., "Molecular characterization of β-thalassemia in Egyptians," *Human Mutation*, vol. 2, no. 1, pp. 48–52, 1993.

[16] Osservatorio Romano sulle Migrazioni—Quinto Rapporto, IDOS, Rome, Italy, 2009.

[17] Dossier Statistico Immigrazione. Caritas / Migrantes—XIX Rapporto sull’Immigrazione, IDOS, Rome, Italy, 2009.

[18] U. Bhardwaj, Y.-H. Zhang, W. Blackburn, L. L. McCabe, and E. R. B. McCabe, "Rapid confirmation of Southeast Asian and Filipino α-thalassemia genotypes from newborn screening specimens," *American Journal of Hematology*, vol. 71, no. 1, pp. 56–58, 2002.

[19] R. Talmaci, J. Traeger-Synodinos, E. Kanavakis, D. Coriu, D. Colita, and L. Gavrila, "Scanning of β-globin gene for identification of β-thalassemia mutation in Romanian population," *Journal of Cellular and Molecular Medicine*, vol. 8, no. 2, pp. 232–240, 2004.

[20] B. Modell, M. Darlison, H. Birgens et al., "Epidemiology of haemoglobin disorders in Europe: an overview," *Scandinavian Journal of Clinical and Laboratory Investigation*, vol. 67, no. 1, pp. 39–69, 2007.

[21] S. Henderson, A. Timbs, J. McCarthy et al., "Incidence of haemoglobinopathies in various populations—the impact of immigration," *Clinical Biochemistry*, vol. 42, no. 18, pp. 1745–1756, 2009.

[22] R. Galanello, A. Eleftheriou, J. Traeger-Synodinos, J. Old, M. Petrou, and M. Angastiniotis, *Prevention of Thalassemia and Other Haemoglobin Disorders*, Thalassaemia International Federation, 2003.

[23] I. Bianco, A. Amato, M. Lerone, D. Ponzini, F. Foglietta, and M. P. Cappabianca, "30 years of thalassemia prevention plain in Latium (Central Italy)," in *Proceedings of the 10th International Conference on Thalassemia Hemoglobinopathies*, Dubai, United Arab Emirates, January 2006, Abstract no. C121.

[24] P. C. Giordano, "Prospective and retrospective primary prevention of Hemoglobinopathies in multiethnic societies," *Clinical Biochemistry*, vol. 42, no. 18, pp. 1757–1766, 2009.